Hypereosinophilic Syndrome
Pipeline by Development Stage
Drug Modality Breakdown
On Market (1)
Approved therapies currently available
Competitive Landscape
4 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Clinical Trials (6)
Total enrollment: 221 patients across 6 trials
Study in Pediatrics With HypEREosinophilic Syndrome (SPHERE)
A Multi-center, Open-label Extension, Safety Study of Mepolizumab in Subjects With Hypereosinophilic Syndrome (HES) From Study 200622
Open-Label Extension Of Intravenous Mepolizumab In Patients With Hypereosinophilic Syndrome
Study to Evaluate Safety and Efficacy of Dexpramipexole (KNS-760704) in Subjects With Hypereosinophilic Syndrome
Anti-Interleukin-5 Antibody to Treat Hypereosinophilic Syndrome
This Record Contains Information About the Mepolizumab Compassionate Use (CU) Product Activities: 104317: CU and Long-Term Access Study of Mepolizumab in HES. 201956:A Long-term Access Programme for Subjects With Severe Asthma 112562: Expanded Access for Patients With Hypereosinophilic
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.